Ezivac%252525252525252525252525252525252520enema

# Ezivac Enema ## Overview Ezivac is a branded saline laxative enema typically containing **sodium phosphates** (monobasic sodium phosphate and dibasic sodium phosphate). It works by osmotic pressure to draw fluid into the colon, stimulating evacuation. ## Primary Indications * Relief of occasional constipation. * Bowel preparation for diagnostic examinations (e.g., sigmoidoscopy, colonoscopy) or surgical procedures. ## Adult Dosing * **Standard dose:** One pre-filled unit (typically 118 mL - 133 mL delivered volume) administered rectally once daily. * **Maximum:** Do not exceed one dose in 24 hours. ## Pediatric Dosing * **Children ≥ 12 years:** Use adult dosing. * **Children 2–11 years:** 59 mL (pediatric size) administered rectally once daily. * **Children < 2 years:** Contraindicated. * *Note: Always consult local institutional protocols, as specific weight-based pediatric guidelines or facility safety policies may supersede general labeling.* ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Significant risk of hyperphosphatemia, hypocalcemia, hypernatremia, and acidosis. Avoid in patients with clinically significant renal insufficiency. * **Hepatic Impairment:** No specific adjustments, but monitor for electrolyte imbalances. ## Contraindications * Hypersensitivity to sodium phosphates. * Congestive heart failure (CHF). * Clinically significant renal impairment. * Suspected bowel obstruction, megacolon, or imperforate anus. * Acute surgical abdomen, appendicitis, or symptoms of inflammatory bowel disease. ## Adverse Effects * **Common:** Rectal irritation, abdominal cramping, anal fissures. * **Serious:** Severe electrolyte disturbances (hyperphosphatemia, hypocalcemia, hyperkalemia, hypernatremia), dehydration, metabolic acidosis, and mucosal ulceration. ## Key Drug Interactions * **Diuretics (Loop/Thiazide):** Increased risk of electrolyte imbalance and dehydration. * **ACE Inhibitors / ARBs:** Increased risk of acute kidney injury secondary to volume depletion. * **Aluminum/Magnesium-based antacids:** Potential for phosphate binding. ## Monitoring * Monitor for signs of dehydration (thirst, decreased urine output). * In high-risk populations, monitor serum electrolytes (Phosphate, Calcium, Sodium, Potassium) and renal function (BUN/SCr) post-administration. ## Clinical Pearls * **Administration:** Positioning the patient on the left side with knees bent often facilitates easier insertion. * **Safety warning:** Ensure the patient is hydrated before use. Gentle insertion is required to prevent rectal perforation, especially in pediatric or elderly populations. * **Duration:** Intended for short-term use only. If no effect is observed after 30 minutes, discontinue and contact a provider. *** *Disclaimer: This information is for educational purposes and reflects general clinical data. Always verify specific dosing, safety requirements, and institutional protocols with current prescribing information or a pharmacist before administration.*